[Study of the cytotoxity against human hepatocellular carcinoma cells induced by the MAGE-1 gene modified dendritic cells].
OBJECTIVE
To genetically modify dendritic cells (DC) with a tumor associated antigen gene MAGE-1 and to observe in vitro the cytotoxic effect induced by this genetically modified DC against human hepatocellular carcinoma (HCC) cell line SMMC7721, thus giving a primary verification of the possibility of this genetically modified DC to induce specific antitumor immunity against HCC and serving as a new type of vaccine.


METHODS
The MAGE-1 gene was inserted into the retrovirus vector LXSN to construct the recombinant retrovirus LMSN. The monocyte-derived DCs were transfected by LMSN and control virus LXSN respectively as well as a third group was set up as non-transfected control. The MAGE-1 gene expression in LMSN transfected DC was identified by Western blot and the in vitro cytotoxities against SMMC7721 induced by three groups of DC were tested by MTT assay.


RESULTS
A recombinant retrovirus LMSN containing the tumor rejection antigen gene MAGE-1 was successfully constructed and the MAGE-1 gene expression in LMSN transfected human monocyte-derived DC was induced. The LMSN transfected DC could induce very high lytic activity against SMMC7721 in vitro with the lytic activity of 78.9%+/-3.6%. Nevertheless, the LXSN transfected DC and non-transfected DC only induced relatively lower lytic activity as 34.7%+/-4.3% and 3.9%+/-2.0%, respectively. The difference of the lytic activities between those three groups as statistically significant (P<0.01).


CONCLUSIONS
The MAGE-1 gene transfected DC can induce higher in vitro cytotoxicity against SMMC7721, suggesting the possibility of this genetically modified DC to induce specific antitumor activity and to serve as a new type of vaccine for HCC.
Liu
B
B
Liver Cancer Institute, Shanghai Medical University, Shanghai 200032, China.
Ye
S
S
He
P
P
Zheng
N
N
Zhao
Y
Y
Sun
R
R
Tang
Z
Z
D000818:Animals; D000951:Antigens, Neoplasm; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D003713:Dendritic Cells / Q000502:physiology*; D015316:Genetic Therapy; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*; D058950:Melanoma-Specific Antigens; D051379:Mice; D009363:Neoplasm Proteins / Q000235:genetics*; D014162:Transfection
D000951:Antigens, Neoplasm; C072011:MAGEA1 protein, human; C489518:Mageb1 protein, mouse; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins